Advances in combating fungal diseases: vaccines on the threshold

被引:159
作者
Cutler, Jim E. [1 ]
Deepe, George S., Jr.
Klein, Bruce S.
机构
[1] Louisiana State Univ Hlth Sci, Dept Pediat, New Orleans, LA 70118 USA
[2] Louisiana State Univ Hlth Sci, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70118 USA
[3] Childrens Hosp, Res Inst Children, New Orleans, LA 70118 USA
[4] Univ Cincinnati, Coll Med, Div Infect Dis, Cincinnati, OH 45267 USA
[5] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53792 USA
[6] Univ Wisconsin, Sch Med & Publ Hlth, Dept Internal Med, Madison, WI 53792 USA
[7] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Microbiol & Immunol, Madison, WI 53792 USA
[8] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Comprehens Canc, Madison, WI 53792 USA
关键词
D O I
10.1038/nrmicro1537
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学]; 100705 [微生物与生化药学];
摘要
The dramatic increase in fungal diseases in recent years can be attributed to the increased aggressiveness of medical therapy and other human activities. Immunosuppressed patients are at risk of contracting fungal diseases in healthcare settings and from natural environments. Increased prescribing of antifungals has led to the emergence of resistant fungi, resulting in treatment challenges. These concerns, together with the elucidation of the mechanisms of protective immunity against fungal diseases, have renewed interest in the development of vaccines against the mycoses. Most research has used murine models of human disease and, as we review in this article, the knowledge gained from these studies has advanced to the point where the development of vaccines targeting human fungal pathogens is now a realistic and achievable goal.
引用
收藏
页码:13 / 28
页数:16
相关论文
共 167 条
[1]
Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection [J].
Abadi, J ;
Pirofski, LA .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) :915-919
[2]
Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen [J].
Abuodeh, RO ;
Shubitz, LF ;
Siegel, E ;
Snyder, S ;
Peng, T ;
Orsborn, KI ;
Brummer, E ;
Stevens, DA ;
Galgiani, JN .
INFECTION AND IMMUNITY, 1999, 67 (06) :2935-2940
[3]
Allendoerfer R, 1998, J IMMUNOL, V160, P6072
[4]
Intrapulmonary response to Histoplasma capsulatum in gamma interferon knockout mice [J].
Allendoerfer, R ;
Deepe, GS .
INFECTION AND IMMUNITY, 1997, 65 (07) :2564-2569
[5]
Allendörfer R, 1999, J IMMUNOL, V162, P7389
[6]
Efficacy of antigen 2/proline-rich antigen cDNA-transfected dendritic cells in immunization of mice against Coccidioides posadasii [J].
Awasthi, S ;
Awasthi, V ;
Magee, AM ;
Coalson, JJ .
JOURNAL OF IMMUNOLOGY, 2005, 175 (06) :3900-3906
[7]
Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation [J].
Bacci, A ;
Montagnoli, C ;
Perruccio, K ;
Bozza, S ;
Gaziano, R ;
Pitzurra, L ;
Velardi, A ;
d'Ostiani, CF ;
Cutler, JE ;
Romani, L .
JOURNAL OF IMMUNOLOGY, 2002, 168 (06) :2904-2913
[8]
Induction of T helper type 1 responses by a polysaccharide deacetylase from Cryptococcus neoformans [J].
Biondo, C ;
Beninati, C ;
Bombaci, M ;
Messina, L ;
Mancuso, G ;
Midiri, A ;
Galbo, R ;
Teti, G .
INFECTION AND IMMUNITY, 2003, 71 (09) :5412-5417
[9]
Dendritic cell-based vaccination against opportunistic fungi [J].
Bozza, S ;
Montagnoli, C ;
Gaziano, R ;
Rossi, G ;
Nkwanyuo, G ;
Bellocchio, S ;
Romani, L .
VACCINE, 2004, 22 (07) :857-864
[10]
A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation [J].
Bozza, S ;
Perruccio, K ;
Montagnoli, C ;
Gaziano, R ;
Bellocchio, S ;
Burchielli, E ;
Nkwanyuo, G ;
Pitzurra, L ;
Velardi, A ;
Romani, L .
BLOOD, 2003, 102 (10) :3807-3814